Angiotensin-converting-enzyme inhibition in stable coronary artery disease.
暂无分享,去创建一个
M. Pfeffer | B. Gersh | M. Rice | M. Domanski | J. Rouleau | E. Braunwald | S. Fowler | N. Geller | J. Hsia | Y. Rosenberg
[1] D. Cox. Regression Models and Life-Tables , 1972 .
[2] K. K. Lan,et al. Discrete sequential boundaries for clinical trials , 1983 .
[3] K. Swedberg,et al. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.
[4] J M Lachin,et al. Implementation of group sequential logrank tests in a maximum duration trial. , 1990, Biometrics.
[5] E. Braunwald. ACE inhibitors--a cornerstone of the treatment of heart failure. , 1991, The New England journal of medicine.
[6] F. Tristani,et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.
[7] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[8] S. Yusuf,et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.
[9] B. Pitt,et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions , 1992, The Lancet.
[10] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[11] Therapy Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure , 1993, The Lancet.
[12] G. Lamas,et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. , 1994, Circulation.
[13] J H Shih,et al. Sample size calculation for complex clinical trials with survival endpoints. , 1995, Controlled clinical trials.
[14] B. Magnani,et al. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction , 1995 .
[15] E. Aliot,et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. , 1995, The New England journal of medicine.
[16] M. Pfeffer,et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. , 1998, The American journal of cardiology.
[17] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[18] Salim Yusuf,et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients , 2000, The Lancet.
[19] V. Fuster,et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 2001, Circulation.
[20] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[21] V. Fuster,et al. AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 2001, Journal of the American College of Cardiology.
[22] S. Yusuf,et al. Ramipril and the development of diabetes. , 2001, JAMA.
[23] E. Antman,et al. ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .
[24] K. Swedberg,et al. Comprehensive guidelines for the diagnosis and treatment of chronic heart failure Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology , 2002, European journal of heart failure.
[25] K. Fox. The EUROPA trial , 2003, The Lancet.
[26] R. Anderson,et al. Deaths: leading causes for 2001. , 2003, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[27] D. Guay. Trandolapril: a newer angiotensin-converting enzyme inhibitor. , 2003, Clinical therapeutics.
[28] K. Fox,et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.
[29] D.,et al. Regression Models and Life-Tables , 2022 .